ETF Opportunities Trust T-Rex 2X Long NVIDIA Daily Target ETF (BATS: NVDX)

에 대한 최신 뉴스 ETF Opportunities Trust T-Rex 2X Long NVIDIA Daily Target ETF (BATS:NVDX)

ETF Opportunities Trust T-Rex 2X Long NVIDIA Daily Target ETF

The Fund, under normal circumstances, invests in swap agreements that provide 200% daily exposure to NVDA equal to at least 80% of its net assets (plus any borrowings for investment purposes). The Fund will enter into one or more swap agreements with major global financial institutions whereby the Fund and the global financial institution will agree to exchange the return earned on an investment by the Fund in NVDA that is equal, on a daily basis, to 200% of the value of the Funds net assets. The Adviser attempts to consistently apply leverage to obtain NVDA exposure for the Fund equal to 200% of the value of its net assets and expects to rebalance the Funds holdings daily to maintain such exposure. As a result of its investment strategies, the Fund will be concentrated in the industry to which NVDA is assigned (i.e., hold 25% or more of its total assets in investments that provide leveraged exposure in the industry to which NVDA is assigned). As of the date of this prospectus, NVDA is assigned to the semiconductors and related devices industry.

T-Rex 2X Long NVIDIA Daily Target ETF

Top 5 Gold ETFs To Shield Your Portfolio From Rising Inflation

Broad U.S. Equity ETFs

ETFs

INTC

INTW

NVDA

NVDX

SMCI

SMCX

예상보다 부진한 인플레이션 지표가 연준 금리 인하에 대한 기대감을 높였지만, 시장은 여전히 백악관의 정책 불확실성에 머물러 있다. 하지만 전반적인 시장 약세에도 불구하고 지난주 일부 ETF는 다른 종목보다 더 좋은 성과를 보였다.

미국 증시 하락세에도 불구하고 상승한 ETF 5종목

S&P500

Analyst Color

Equities

News

Tech

AAPL

PLTR

SOXL

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

Technology Select Sector SPDR Fund(NYSE:XLK)가 5% 이상 하락하고 광범위한 시장 성과를 측정하는 S&amp;P 500 지수보다 저조한 성과를 거두면서 8월 2일로 끝난 주에 기술 분야가 급락했다. 지난주에 해당 부문을 끌어온 요인에 대한 요약과 이러한 주식이 단기 및 중기적으로 어디로 향하고 있는지에 대한 전망은 다음과 같다.

기술주 급락에 Invesco QQQ Trust는 조정 구간 진입, 엔비디아는 지난주 5% 이상 하락

For many, the dream of <a href="https://in.benzinga.com/personal-finance/25/03/44368831/retiring-in-months-with-700000-62-year-old-plans-500000-move-to-dividends-should-i-go-all-in-on-jepi-jepq-or-riskier-plays">retiring</a> comfortably is built on decades of disciplined investing in the right assets.
Countless people have grown their wealth in time so they can live comfortably from the returns of their <a href="https://in.benzinga.com/news/25/02/43901059/ray-dalios-holy-grail-investment-strategy-why-10-15-diversified-investments-could-make-you-a-fortune">investments</a>, and Vanguard is a cornerstone for many of these success stories. Still, even the most seasoned investors can face moments of doubt, particularly during market downturns or political uncertainty.
This is the case of a 73-year-old retiree who has relied on Vanguard for more than a decade but is now questioning his approach amid market volatility.
Don't Miss:
<ul>
<li>Many are using retirement income calculators to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on what&#8217;s behind this formula.</a></li>
<li>Markets are down – <a href="https://www.benzinga.com/money/casa-shares">diversify your portfolio by investing in real estate with as little as $100, and receive a share of potential rental income and property gains</a>.</li>
</ul>
<h2 class="wp-block-heading">Remember Lucy Horsnby? Just heard her on NPR.&nbsp;</h2>
The Redditor has been with Vanguard since 2013, maintaining a portfolio consisting of 70% Vanguard Total Stock Market Index Fund (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTSAX#NASDAQ">VTSAX</a>) and 30% Vanguard LifeStrategy Moderate Growth Fund (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSMGX#NASDAQ">VSMGX</a>), achieving an average return of 9.9%.
&#8220;The current administration scares me to death; I&#8217;ve lost ~10% of my account in the last month. I want to shelter myself from the current downturn and specifically divest myself from [Tesla Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tsla#NASDAQ">TSLA</a>)] and [Meta Platforms Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/meta#NASDAQ">META</a>)]. Where do I go in Vanguard?&#8221; he asked.
Trending: BlackRock is calling 2025 the year of alternative assets. <a href="https://www.benzinga.com/money/masterworks">One firm from NYC has quietly built a group of 60,000+ investors who have all joined in on an alt asset class previously exclusive to billionaires like Bezos and Gates.</a>
The Reddit community responded to the poster with a mix of caution and practical advice, so let&#8217;s dive into those.
<h2 class="wp-block-heading">73-Year-Old Investor With All-Vanguard Portfolio Afraid of Market Volatility–Reddit Responds</h2>
Rebalance to a More Conservative Portfolio
The consensus among commenters was that the investor&#8217;s current portfolio is too aggressive for his age and risk tolerance, so many suggested rebalancing to a more conservative combo.
&#8220;It&#8217;s impossible to shelter yourself from the current downturn and still own stocks. Your allocation is aggressive for a typical 73-year-old. VSMGX is 60/40 stocks/bonds. VTSAX is 100% stock. Given that VTSAX is 70% of the total, overall you are 88% stock,&#8221; a Redditor suggested.
A user responded to this comment, agreeing with it and recommending a more conservative allocation.
&#8220;Yeah, that&#8217;s where you should be at like age 53, not age 73. You should have a much more conservative portfolio. Are you planning to live to 120? If not, let&#8217;s be real: You need this money to last you another 10-20 years, probably. Get into a more conservative portfolio.&#8221;
A Redditor acknowledged the investor&#8217;s past success but advised him to shift toward bonds to reduce risk.
&#8220;You have basically won by going with a very aggressive 70% VTSAX and 30% VSMGX for the last 13 years. After these fantastic gains, I think it would be good to add a lot more bonds because you are older now and because you are worried about this downturn,&#8221; he said.
&#8220;You are way too heavy in stocks for someone who is 73, particularly if this administration scares you,&#8221; a comment reads.
&#8220;You are still up over 10% the past year; reallocate into bonds and a healthy amount of cash even. You're good,&#8221; another Redditor said.
See Also: Can you guess how many Americans successfully retire with $1,000,000 saved?<a href="https://www.benzinga.com/money/1milsaved"> The percentage may shock you</a>.
Avoid Emotional Decisions and Stay the Course
Many Redditors cautioned against making any emotional decisions based on short-term market fluctuations.
&#8220;Stop looking at your portfolio and realize that this 10% drop in your portfolio really means nothing in the context of the long-term gains your portfolio has had. In other words, close the laptop and go live your life,&#8221; a comment says.
&#8220;You have lost the gains of the last 6 months. Calm down,&#8221; a Redditor wrote.
A commenter said he relates to the investor&#8217;s concerns and shared what actions he&#8217;s thinking of taking to avoid panic selling and unnecessary risk.
&#8220;Your risk tolerance is decreasing. I can relate. I&#8217;m close to retirement and the latest activity in the market made me rethink my allocation. I&#8217;ve been aggressive but now want to do more capital preservation. I dropped to 60% equities and 40% bonds; my wife wants to drop it even further. I don&#8217;t want to make panic-driven decisions and predict downturns. But I do want to have a portfolio that I can sleep well at night. I don&#8217;t need to be focused aggressively on capital appreciation anymore and can be more conservative in my investments,&#8221; he shared.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></li>
<li>The average American couple has saved this much money for retirement —<a href="http://www.benzinga.com/money/smartasset"> How do you compare</a>?</li>
</ul>

Personal Finance

TSLA

VSMGX

VTSAX

Retired Investor With 13-Year Vanguard Strategy Asks 'Where Do I Go In Vanguard?' – Wants Out Of Tesla And Meta Amid Market Fears

A federal judge has taken issue with the&nbsp;Trump administration&nbsp;for its handling of Venezuelan deportation flights, highlighting a lack of adequate response to a court order.
What Happened: U.S. District Judge James Boasberg criticized the administration for not providing sufficient details about Venezuelan deportation flights, according to <a href="https://thehill.com/regulation/court-battles/5206108-trump-administration-venezuelan-deportation-flights/">The Hill</a>. The Justice Department missed a deadline to submit flight information, opting instead for a declaration from an Immigrations and Customs Enforcement official.
The declaration indicated that &#8220;Cabinet Secretaries are currently actively considering whether to invoke the state secrets privilege.&#8221; Judge Boasberg, appointed by former President Barack Obama, demanded an update from someone directly involved in the discussions by Friday. By Tuesday, officials must explain their non-compliance with court orders that block Trump&#8217;s use of the Alien Enemies Act.
The Justice Department maintains it adhered to Boasberg's written order, arguing the oral order was not binding. Meanwhile, the American Civil Liberties Union claims the government could have returned deportees until they were in foreign custody. The administration has suggested invoking the state secrets privilege to withhold sensitive information.
See Also: <a href="https://www.benzinga.com/25/03/44389618/trump-press-secretary-blasted-by-french-mep-over-statue-of-liberty-reaction-if-hundreds-of-thousands-of-young-americans-had-not-landed-on-our-beaches">Trump Press Secretary Blasted By French MEP Over Statue Of Liberty Reaction: &#8216;If Hundreds Of Thousands Of Young Americans Had Not Landed On Our Beaches&#8230;&#8217;</a>
Why It Matters: This legal challenge comes amid Trump&#8217;s ambitious deportation plans, which aim to remove <a href="https://in.benzinga.com/news/25/01/43216758/well-go-as-far-as-im-allowed-trumps-plan-with-immigrants-starts-with-1-million-deportations">one million undocumented immigrants</a> in his first year back in office. Trump had expressed his willingness to use the National Guard to achieve this goal, stating he will go &#8220;as far as I&#8217;m allowed to go, according to the laws of our country.&#8221;
Despite the controversy, a <a href="https://in.benzinga.com/news/25/02/43769836/trump-gains-trust-of-majority-on-americans-on-immigration-and-economy">recent poll</a> indicates that 52% of Americans trust Trump's handling of immigration. This trust is particularly strong among Republicans, with 87% expressing confidence in his immigration policies. However, the administration&#8217;s approach to deportations and its legal challenges could impact public perception and policy implementation.
Image via Shutterstock
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

Politics

General

Trump Administration Failed To Respond To Court Order On Deportation Flights: Explain Non-Compliance By Tuesday, Says Judge

Franco-Nevada (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNV#NYSE">FNV</a>) has outperformed the market over the past 10 years by 1.35% on an annualized basis producing an average annual return of 11.99%. Currently, Franco-Nevada has a market capitalization of $29.95 billion. 
Buying $1000 In FNV: If an investor had bought $1000 of FNV stock 10 years ago, it would be worth $3,061.01 today based on a price of $155.53 for FNV at the time of writing.
<h3>Franco-Nevada's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742514312_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much $1000 Invested In Franco-Nevada 10 Years Ago Would Be Worth Today

Interactive Brokers Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBKR#NASDAQ">IBKR</a>) has outperformed the market over the past 15 years by 6.17% on an annualized basis producing an average annual return of 17.27%. Currently, Interactive Brokers Group has a market capitalization of $19.16 billion. 
Buying $1000 In IBKR: If an investor had bought $1000 of IBKR stock 15 years ago, it would be worth $10,916.20 today based on a price of $175.80 for IBKR at the time of writing.
<h3>Interactive Brokers Group's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742513408_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

IBKR

Here's How Much You Would Have Made Owning Interactive Brokers Group Stock In The Last 15 Years

Ventas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTR#NYSE">VTR</a>) has outperformed the market over the past 5 years by 2.99% on an annualized basis producing an average annual return of 21.38%. Currently, Ventas has a market capitalization of $29.60 billion. 
Buying $100 In VTR: If an investor had bought $100 of VTR stock 5 years ago, it would be worth $294.39 today based on a price of $67.71 for VTR at the time of writing.
<h3>Ventas's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742512511_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Ventas 5 Years Ago Would Be Worth This Much Today

Enterprise Prods Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPD#NYSE">EPD</a>) has outperformed the market over the past 5 years by 1.27% on an annualized basis producing an average annual return of 19.66%. Currently, Enterprise Prods Partners has a market capitalization of $74.00 billion. 
Buying $1000 In EPD: If an investor had bought $1000 of EPD stock 5 years ago, it would be worth $2,565.84 today based on a price of $34.14 for EPD at the time of writing.
<h3>Enterprise Prods Partners's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742511608_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Enterprise Prods Partners 5 Years Ago Would Be Worth Today

Guidewire Software (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWRE#NYSE">GWRE</a>) has outperformed the market over the past 10 years by 3.73% on an annualized basis producing an average annual return of 14.37%. Currently, Guidewire Software has a market capitalization of $16.23 billion. 
Buying $100 In GWRE: If an investor had bought $100 of GWRE stock 10 years ago, it would be worth $375.00 today based on a price of $193.46 for GWRE at the time of writing.
<h3>Guidewire Software's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742510712_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GWRE

Here's How Much You Would Have Made Owning Guidewire Software Stock In The Last 10 Years

Earnings

Citigourp Global Markets 2% Protected Notes Linked To The Djia

CORRECTION: PDD Holdings Q4 2024 Adj EPS $2.76 Misses $19.81 Estimate, Sales $15.15B Miss $115.38B Estimate

Investor jitters about Trump's tariffs and global debt levels are stoking recession fears and driving up<a href="https://www.benzinga.com/markets/commodities/25/01/42759408/gold-prices-to-climb-7-in-2025-amid-trumps-return-to-white-house-and-geopolitical-tensions-momentum-is-taking-back-over"> gold prices</a>. Royal Gold (NASDAQ:<a href="https://www.benzinga.com/quote/RGLD"> RGLD</a>) may be worth a look at if you're an investor who wants to capitalize on the trend. The<a href="https://www.insidermonkey.com/blog/royal-gold-inc-rgld-among-the-best-gold-dividend-stocks-to-buy-according-to-analysts-1468571/"> Insider Monkey</a> website reports over 40 hedge funds are invested in this Royal Gold and there may be more upside. Could this stock be a winner in your portfolio too?&nbsp;
Royal Gold has a simple but profitable business model. It offers financing for mining operations worldwide in exchange for a percentage of the mine's total output. However, the company's name does not encompass the full scope of its operations. Royal Gold also finances various industrial metal operations, including copper, zinc, and silver.&nbsp;
Don't Miss:
<ul>
<li><a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.</li>
<li>If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/money/arrived-private-credit-fund">7-9% target yield with monthly dividends would you invest in it</a>?</li>
</ul>
With that said, it's the gold that has everyone excited. Analysts at some of the world's largest investment banks believe gold prices will continue surging for much of 2025.<a href="https://www.goldmansachs.com/insights/articles/gold-prices-are-forecast-to-rise-another-8-percent-this-year"> Goldman Sachs</a> recently upped its target price for gold from $2,890 to $3,100 per ounce, while JPMorgan's predictions of gold hitting $3,000 per ounce have already come to pass.
Considering that Royal Gold is coming off a strong 2024, those predictions are music to shareholders' ears. The Denver-based company's<a href="https://royalgold.com/investors/financial-reports/default.aspx"> year-end report for 2024</a> featured several impressive results, which included:
<ul>
<li>$332 million in net income &#8211; a 39% increase over the previous year</li>
<li>$719.4 million in revenue &#8211; a 19% increase over the previous year</li>
<li>$529.5 million in operating cash flow &#8211; a 27% increase over the previous year</li>
<li>$346.4 million in adjusted net income ($5.26 per share)</li>
</ul>
The revenue, operating cash flow, and earnings figures are all record totals. Royal Gold also met its upper-end expectations for gold sales, while surpassing expectations for copper and the rest of its portfolio. According to the report, gold sales accounted for 76% of Royal Gold's revenue in 2024. That puts Royal Gold in a great position to profit from the increase in gold prices predicted by <a href="https://www.jpmorgan.com/insights/global-research/outlook/market-outlook">JPMorgan</a> and<a href="https://www.benzinga.com/25/03/44200350/salesforce-ai-expansion-sparks-analyst-optimism-400-price-forecast-set"> Goldman</a>.
Trending: The secret weapon in billionaire investor portfolios that you almost certainly don't own yet. <a href="https://www.benzinga.com/money/masterworks">See which asset class has outpaced the S&amp;P 500 (1995-2024) – and with near-zero correlation.</a>
"Our business is designed to deliver leverage to gold, and our 2024 results demonstrate the direct relationship between a strong and rising gold price and Royal Gold&#8217;s financial performance," CEO Bill Heissenbuttel said in the earnings release. "This leverage is evidenced by the impressive percentage increases in operating cash flow and net income, both of which exceeded that of revenue. The foundation of our performance is our diversified portfolio."
Royal Gold's strong 2024 performance was also reflected in its dividend, which increased for the 24th consecutive year. The company announced the 2024 dividend of $1.60 per share will increase to $1.80 in 2025. That's a 12.5% increase and shareholders could get an even bigger payout if gold prices continue to rise as predicted. This stock has the potential to be a strong performer for passive income investors in 2025.
Read Next:
<ul>
<li>Have $200K saved?<a href="https://www.benzinga.com/money/have-200k-saved-heres-how-to-turn-it-into-lasting-wealth"> Here's how to turn it into lasting wealth</a></li>
<li><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></li>
</ul>

Gold Is Surging -- Could Buying This Gold Dividend (RGLD) Stock Be The Best Way To Profit On The Trend?

Streaming giant Netflix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) has launched many video games over the years. It has its first MMO coming soon, adding to the company&#8217;s library of games based <a href="https://www.benzinga.com/general/entertainment/24/06/39213738/netflix-reality-show-games-and-chill-streaming-giant-sees-success-from-interactive-games-ba">on its own series </a>and external characters.
What Happened: Netflix recently announced it will launch Spirit Crossing, adding to its lineup of content and exclusives for subscribers<a href="https://www.benzinga.com/general/entertainment/24/11/41821069/netflix-stock-hits-all-time-highs-company-confirms-stranger-things-season-5-for-2025"> later this year.</a>
"Prepare to adventure into a joyful world with Spirit Crossing, a massively cooperative life sim designed to encourage friendship and make the world feel a little less lonely," the company <a href="https://about.netflix.com/en/news/spry-foxs-spirit-crossing-comes-to-netflix-later-this-year">said </a>of the new game.
The game comes from Spry Fox, which Netflix acquired in 2022. The studio has previously released games like Triple Town, Alphabear and Cozy Grove.
Netflix says Spirit Crossing will be the biggest game ever released by Spry Fox.
An MMO, which stands for massively multiplayer online, is an online video game that allows gamers to take part in the same virtual world. Netflix said players will be encouraged to work together with other players to build and decorate their homes and villages, explore the wilderness, follow friends and make new friends to gather resources together.
Interested gamers can<a href="https://playspiritcrossing.com/"> sign up</a> for a closed alpha of the game ahead of its full release.
Read Also: <a href="https://www.benzinga.com/news/earnings/25/01/43114866/netflix-q4-earnings-record-subscribers-nfl-squid-game-push-past-highest-expectations">Netflix Q4 Earnings: Record Subscribers, NFL, &#8216;Squid Game&#8217; Push Past &#8216;Highest Expectations&#8217;</a>
 Why It's Important: Netflix has launched games for years and acquired several gaming companies. This could mark one of the streaming company's most ambitious projects in the gaming space to date.
The launch of an MMO game might keep players interested for longer if done correctly and could provide valuable minutes in game for Netflix's engagement statistics as players customize their world and adventure together.
Cozy games — which are non-violent, emphasizing relaxation — have grown in popularity and Netflix entered the market with a launch from a company that had success in the space. While this game won&#8217;t get as many headlines as its game based on &#8220;Squid Game,&#8221; this could be a storyline to watch for the streamer in 2025.
Since this game isn&#8217;t based on existing Netflix property, the streaming giant has the opportunity to go in reverse order and launch future shows and movies if the game is successful and could also launch consumer products and licensed goods around the game.
Along with announcing Spirit Crossing, Netflix also announced several other upcoming games.
<ul>
<li>The Electric State &#8211; Kid Cosmo: a puzzle game based on the recently released movie "The Electric State" that is available now.</li>
<li>Steel Paws: adventure game from Japanese game developer Yu Suzuki, known for his work on Out Run, Shenmue and Virtua Fighter. The game is scheduled for a March 25 release.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/entertainment/24/06/39213738/netflix-reality-show-games-and-chill-streaming-giant-sees-success-from-interactive-games-ba">Netflix Reality Show Games And Chill? Streaming Giant Sees Success From Interactive Games Based On Hit Shows</a></li>
</ul>
Photo: Courtesy Netflix

Entertainment

Gaming

NFLX

Netflix To Launch First MMO Video Game: Is It The Streaming Company's Biggest Gaming Bet Yet?

Hilton Worldwide Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLT#NYSE">HLT</a>) has outperformed the market over the past 5 years by 8.9% on an annualized basis producing an average annual return of 27.29%. Currently, Hilton Worldwide Holdings has a market capitalization of $55.80 billion. 
Buying $100 In HLT: If an investor had bought $100 of HLT stock 5 years ago, it would be worth $366.19 today based on a price of $231.91 for HLT at the time of writing.
<h3>Hilton Worldwide Holdings's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742509807_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Hilton Worldwide Holdings 5 Years Ago Would Be Worth Today

Eaton Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETN#NYSE">ETN</a>) has outperformed the market over the past 10 years by 5.39% on an annualized basis producing an average annual return of 16.03%. Currently, Eaton Corp has a market capitalization of $116.74 billion. 
Buying $100 In ETN: If an investor had bought $100 of ETN stock 10 years ago, it would be worth $435.44 today based on a price of $295.40 for ETN at the time of writing.
<h3>Eaton Corp's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742508913_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Eaton Corp 10 Years Ago Would Be Worth This Much Today

In the latest quarter, 12 analysts provided ratings for Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), showcasing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Cigna Group, revealing an average target of $366.0, a high estimate of $390.00, and a low estimate of $339.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 8.16%. 
<img src="https://www.benzinga.com/files/images/story/2025/1742508078_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Cigna Group. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$365.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$375.00</td>
<td>$390.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$341.00</td>
<td>$370.00</td>
</tr>
<tr>
<td>Kevin Caliendo</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$390.00</td>
<td>$410.00</td>
</tr>
<tr>
<td>Jessica Tassan</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$348.00</td>
<td>$394.00</td>
</tr>
<tr>
<td>Michael Wiederhorn</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$375.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>John Ransom</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Strong Buy</td>
<td>$360.00</td>
<td>$415.00</td>
</tr>
<tr>
<td>Raj Kumar</td>
<td>Stephens &amp; Co.</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$380.00</td>
<td>$410.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$350.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Erin Wright</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$379.00</td>
<td>$403.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$339.00</td>
<td>$420.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$390.00</td>
<td>$420.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Cigna Group. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Cigna Group compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Cigna Group's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Cigna Group's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Cigna Group analyst ratings.</a>
<h2>All You Need to Know About Cigna Group</h2>
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM and specialty pharmacy services, which were greatly expanded by its 2018 merger with Express Scripts, are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense, and it recently won a deal with top-tier insurer Centene. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, and the company operates mostly in the US with 17 million US and 2 million international medical members covered as of September 2024.
<h3>Cigna Group: Financial Performance Dissected</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: Cigna Group's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 28.66%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Cigna Group's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 2.17%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Cigna Group's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 3.43%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Cigna Group's ROA excels beyond industry benchmarks, reaching 0.91%. This signifies efficient management of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.78.
<h2>How Are Analyst Ratings Determined?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Cigna Group Stock: A Deep Dive Into Analyst Perspectives (12 Ratings)

Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on Bridge Investment Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRDG#NYSE">BRDG</a>) in the last three months.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $10.9, with a high estimate of $12.00 and a low estimate of $10.00. This current average reflects an increase of 2.83% from the previous average price target of $10.60. 
<img src="https://www.benzinga.com/files/images/story/2025/1742508065_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of Bridge Investment Group among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$11.00</td>
<td>$11.50</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$11.50</td>
<td>$10.00</td>
</tr>
<tr>
<td>Brennan Hawken</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$12.00</td>
<td>$7.50</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$10.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Kenneth Worthington</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$10.00</td>
<td>$12.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Bridge Investment Group. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Bridge Investment Group compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Bridge Investment Group's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
To gain a panoramic view of Bridge Investment Group's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/BRDG/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Bridge Investment Group analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Get to Know Bridge Investment Group Better</h2>
Bridge Investment Group Holdings Inc is a vertically integrated investment manager, diversified across specialized asset classes. The company combines its operating platform with dedicated teams of investment professionals focused on various specialized and synergistic investment platforms, including real estate, credit, renewable energy, and secondaries strategies. Its products and vertically integrated structure allow it to capture new market opportunities and serve investors with various investment objectives. The Company operates as one business, a fully integrated real estate investment manager.
<h3>Bridge Investment Group's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Bridge Investment Group's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 9.83% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Financials sector.
Net Margin: Bridge Investment Group's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -9.95%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Bridge Investment Group's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -11.94%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Bridge Investment Group's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -0.82%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Bridge Investment Group's debt-to-equity ratio surpasses industry norms, standing at 5.4. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>The Basics of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BRDG

What Analysts Are Saying About Bridge Investment Group Stock

In the last three months, 7 analysts have published ratings on Celldex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDX#NASDAQ">CLDX</a>), offering a diverse range of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $60.0, along with a high estimate of $80.00 and a low estimate of $36.00. A 10.71% drop is evident in the current average compared to the previous average price target of $67.20. 
<img src="https://www.benzinga.com/files/images/story/2025/1742508047_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
A clear picture of Celldex Therapeutics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Judah Frommer</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Overweight</td>
<td>$46.00</td>
<td>-</td>
</tr>
<tr>
<td>Richard Law</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$36.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$80.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$80.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Trung Huynh</td>
<td>UBS</td>
<td>Announces</td>
<td>Buy</td>
<td>$44.00</td>
<td>-</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$67.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$67.00</td>
<td>$67.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Celldex Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Celldex Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Celldex Therapeutics's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Celldex Therapeutics's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CLDX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Celldex Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About Celldex Therapeutics</h2>
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
<h3>Financial Insights: Celldex Therapeutics</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3 months period, Celldex Therapeutics faced challenges, resulting in a decline of approximately -71.56% in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Celldex Therapeutics's net margin excels beyond industry benchmarks, reaching -4007.83%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Celldex Therapeutics's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -6.14%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Celldex Therapeutics's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -5.83%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Celldex Therapeutics's debt-to-equity ratio is below the industry average at 0.01, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: Simplified</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CLDX

7 Analysts Have This To Say About Celldex Therapeutics

7 analysts have shared their evaluations of Allegiant Travel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGT#NASDAQ">ALGT</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Allegiant Travel, revealing an average target of $94.0, a high estimate of $110.00, and a low estimate of $61.00. Surpassing the previous average price target of $77.14, the current average has increased by 21.86%.
<img src="https://www.benzinga.com/files/images/story/2025/1742508030_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of Allegiant Travel among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thomas Wadewitz</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$61.00</td>
<td>$93.00</td>
</tr>
<tr>
<td>Ravi Shanker</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$95.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Andrew Didora</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Underperform</td>
<td>$95.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>Brandon Oglenski</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$100.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Catherine O'Brien</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$92.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Christopher Stathoulopoulos</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Neutral</td>
<td>$105.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Savanthi Syth</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$110.00</td>
<td>$75.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Allegiant Travel. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Allegiant Travel compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Allegiant Travel's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Allegiant Travel's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ALGT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Allegiant Travel analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Discovering Allegiant Travel: A Closer Look</h2>
Allegiant Travel Co is a leisure travel company focused on providing travel and leisure services and products to residents of under-served cities in the United States. It operates a low-cost, low utilization passenger airline marketed to leisure travelers in under-served cities, allowing it to sell air transportation both on a stand-alone basis and bundled with the sale of air-related and third-party services and products. In addition, it provides air transportation under fixed-fee flight arrangements. In connection with its leisure travel focus, the company has opened Sunseeker Resort Charlotte Harbor, equipped with several guestrooms and food and beverage outlets. The company's operating segments are the Airline, which generates maximum revenue, and Sunseeker Resort.
<h3>Allegiant Travel: Financial Performance Dissected</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Allegiant Travel's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 2.73%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Industrials sector.
Net Margin: Allegiant Travel's net margin excels beyond industry benchmarks, reaching -34.45%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Allegiant Travel's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -18.1%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Allegiant Travel's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -4.69%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Allegiant Travel's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.97.
<h2>How Are Analyst Ratings Determined?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALGT

Where Allegiant Travel Stands With Analysts

In the preceding three months, 4 analysts have released ratings for Spire (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SR#NYSE">SR</a>), presenting a wide array of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $82.0, a high estimate of $85.00, and a low estimate of $78.00. Observing a 10.32% increase, the current average has risen from the previous average price target of $74.33. 
<img src="https://www.benzinga.com/files/images/story/2025/1742508023_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Spire. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stephen Byrd</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$78.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Richard Sunderland</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$85.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Gabriel Moreen</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$82.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Paul Fremont</td>
<td>Ladenburg Thalmann</td>
<td>Announces</td>
<td>Buy</td>
<td>$83.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Spire. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Spire compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Spire's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Spire's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Spire analyst ratings.</a>
<h2>Discovering Spire: A Closer Look</h2>
Spire Inc is a public utility holding company with three reportable business segments: Gas Utility, Gas Marketing and Midstream. The Gas Utility segment includes the regulated operations of Laclede Gas, Alabama Gas Corporation ('Alagasco') changed its name to Spire Alabama Inc. effective September 1, 2017, and Laclede Gas Company changed its name to Spire Missouri Inc. effective August 30, 2017. The Gas Utility segment generates a majority of the company's revenue but is subject to seasonal fluctuations. The Gas Marketing segment includes Laclede Energy Resources, Inc, whose operations include the marketing of natural gas and related activities on a non-regulated basis and the Midstream segment includes transportation and storage of natural gas. Maximum revenue from residential area.
<h3>Key Indicators: Spire's Financial Health</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Negative Revenue Trend: Examining Spire's financials over 3 months reveals challenges. As of 31 December, 2024, the company experienced a decline of approximately -11.56% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Utilities sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Spire's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 11.58%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 2.56%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Spire's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 0.7%, the company may face hurdles in achieving optimal financial performance.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 1.59, caution is advised due to increased financial risk.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Spire's Future

In the latest quarter, 9 analysts provided ratings for Blue Owl Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OWL#NYSE">OWL</a>), showcasing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Blue Owl Capital, presenting an average target of $27.78, a high estimate of $32.00, and a low estimate of $22.00. This current average has increased by 4.01% from the previous average price target of $26.71. 
<img src="https://www.benzinga.com/files/images/story/2025/1742508016_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A clear picture of Blue Owl Capital's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$22.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Announces</td>
<td>Overweight</td>
<td>$29.00</td>
<td>-</td>
</tr>
<tr>
<td>Brian McKenna</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$32.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Brian McKenna</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$32.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Christopher Allen</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Buy</td>
<td>$30.00</td>
<td>-</td>
</tr>
<tr>
<td>Glenn Schorr</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$26.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Bill Katz</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$28.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$24.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Crispin Love</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$27.00</td>
<td>$25.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Blue Owl Capital. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Blue Owl Capital compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Blue Owl Capital's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Blue Owl Capital's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/OWL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Blue Owl Capital analyst ratings.</a>
<h2>Get to Know Blue Owl Capital Better</h2>
Blue Owl Capital Inc is an alternative asset management firm. The company deploys private capital across Credit, GP Strategic Capital, and Real Estate platforms on behalf of institutional and private wealth clients. The company conducts its operations through Blue Owl Capital Holdings LP (Blue Owl Holdings) and Blue Owl Capital Carry LP (Blue Owl Carry). Its investor base includes a diversified mix of institutional investors, including public and private pension funds, endowments, foundations, family offices, private banks, high-net-worth individuals, asset managers, and insurance companies. The company generates substantially all of its revenues in the United States.
<h3>Financial Insights: Blue Owl Capital</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Positive Revenue Trend: Examining Blue Owl Capital's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 27.8% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Financials sector.
Net Margin: Blue Owl Capital's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 3.29%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 1.0%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Blue Owl Capital's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.19%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Blue Owl Capital's debt-to-equity ratio is below the industry average at 1.4, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down Blue Owl Capital: 9 Analysts Share Their Views

SS&amp;C Technologies Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSNC#NASDAQ">SSNC</a>) has outperformed the market over the past 15 years by 11.72% on an annualized basis producing an average annual return of 22.82%. Currently, SS&amp;C Technologies Hldgs has a market capitalization of $20.39 billion. 
Buying $100 In SSNC: If an investor had bought $100 of SSNC stock 15 years ago, it would be worth $2,184.08 today based on a price of $82.34 for SSNC at the time of writing.
<h3>SS&amp;C Technologies Hldgs's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742508012_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SSNC

Here's How Much You Would Have Made Owning SS&C Technologies Hldgs Stock In The Last 15 Years

Armata Pharmaceuticals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ARMP#AMEX">ARMP</a>) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.35) by 34.29 percent. This is a 58.18 percent increase over losses of $(0.55) per share from the same period last year. The company reported quarterly sales of $1.24 million which missed the analyst consensus estimate of $1.56 million by 20.83 percent. This is a 19.18 percent decrease over sales of $1.53 million the same period last year.

Earnings Beats

Earnings Misses

ARMP

Armata Pharmaceuticals Q4 2024 GAAP EPS $(0.23) Beats $(0.35) Estimate, Sales $1.24M Miss $1.56M Estimate

Nvidia Is Up Over 150% YTD, But Some Are Flagging Risks – Trade Your Expectation Either Way With REX Shares Leveraged ETFs

AMZN

FEPI

GOOG

MSFT

NVDQ

Screenshot 2024-08-26 at 7.19.14 PM

지난주 <a href="https://www.benzinga.com/economics/macro-economic-events/25/03/44341328/stocks-enter-correction-zone-tariff-fears-hammer-consumer-confidence-inflation-worries-hit-32-year-highs-this-week-in-markets" target="_blank" rel="noopener">미국 증시는 4주 연속 하락세</a>로 마감하며 2022년 5월 이후 최장 하락을 기록했다.
S&amp;P 500 지수는 2월 고점 대비 10% 하락하며 조정 영역에 진입했다. 투자자들은 무역 긴장과 정부 지출 삭감에 대한 불안감이 계속되고 있다. 예상보다 부진한 인플레이션 지표가 연준 금리 인하에 대한 기대감을 높였지만, 시장은 여전히 백악관의 정책 불확실성에 머물러 있다.
하지만 전반적인 시장 약세에도 불구하고 지난주 일부 ETF는 다른 종목보다 더 좋은 성과를 보였다.
<h3 class="wp-block-heading">수익률 상위 5개 ETF</h3>
다음 ETF들은 광범위한 시장 변동성 속에서도 기회를 강조하고 있다.
GraniteShares 2x Long INTC Daily ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTW#NASDAQ">INTW</a>): <a href="https://www.benzinga.com/etfs">레버리지 ETF</a>이며, 인텔(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) 주식이 AI 지원 칩 수요에 대한 기대감 속에서 다시 상승세를 보이자 급등했다.
<ul>
<li>주간 수익률: 32.71%</li>
<li>운용수수료: 1.3%</li>
</ul>
Defiance Daily Target 2X Long SMCI ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCX#NASDAQ">SMCX</a>): 강력한 실적과 증가하는 AI 서버 수요에 의해 촉발된 슈퍼마이크로컴퓨터(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) 주가 상승은 이 ETF의 수익률을 끌어올렸다.
<ul>
<li>주간 수익률: 17.62%</li>
<li>운용수수료: 1.29%</li>
</ul>
T-Rex 2X Inverse Ether Daily Target ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ETQ#BATS">ETQ</a>): 암호화폐 하락에서 이익을 얻는 이 인버스 ETF는 이더리움 가격 하락 덕분에 상승했다.
<ul>
<li>주간 수익률: 15.85%</li>
<li>운용수수료: 1.25%</li>
</ul>
T-Rex 2X Long NVIDIA Daily Target ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/NVDX#BATS">NVDX</a>): 엔비디아(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) AI 칩 시장에서의 지속적인 지배력은 이 레버리지 ETF를 상승시켰다.
<ul>
<li>주간 수익률: 14.62%</li>
<li>운용수수료: 1.05%</li>
</ul>
Global X Silver Miners ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SIL#NYSE">SIL</a>): 경제 불확실성 시 안전 자산 수요로 인한 은 가격 상승은 은 광산주와 이 ETF를 상승시켰다.
<ul>
<li>주간 수익률: 8.82%</li>
<li>운용수수료: 0.65%</li>
</ul>
<h2 class="wp-block-heading">지난주 시장을 움직인 요인</h2>
트럼프 대통령의 무역 관세 보류와 일론 머스크의 정부효율부가 주도한 갑작스러운 지출 삭감으로 인해 투자자들의 불안감이 고조되고 있다. 2월 CPI 는 전년 동월 대비 2.8% 상승하여 컨센서스 2.9%보다 낮았지만, 이렇게 예상보다 완만한 인플레이션 수치에도 시장은 백악관의 정책 조치에 집착하고 있다.
트럼프는 EU가 미국산 위스키에 대한 50%의 관세를 인하하면 유럽산 와인에 200%의 관세를 부과하고 캐나다산 철강과 알루미늄에 대한 관세를 두 배로 올리겠다고 공언하며, 자동차 관세도 위협했다.
지난주 소비자 심리지수가 하락하고 장기 인플레이션 기대치가 1993년 이후 최고치를 기록했다. 경제 불확실성에 따라 <a href="https://www.benzinga.com/etfs/specialty-etfs/25/03/44335436/gold-etfs-shine-as-spot-price-tops-3000-during-safe-haven-demand" target="_blank" rel="noopener">금 가격은 온스당 3,000달러를 기록했으며</a> 지난 11주 중 10주 동안 상승했다.
지난 주말에는 정부 셧다운을 피할 수 있다는 확인과 새로운 무역 뉴스의 부재로 시장이 소폭 반등했다. 이번 주 연준 FOMC 회의에서는 금리동결이 예상되지만, 인플레이션이 지속되는 가운데 성장 둔화인 스태그플레이션에 대한 우려가 커지고 있다.
이미지: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Technology Select Sector SPDR Fund(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)가 5% 이상 하락하고 광범위한 시장 성과를 측정하는 S&amp;P 500 지수보다 저조한 성과를 거두면서 8월 2일로 끝난 주에 <a href="https://www.benzinga.com/markets/24/08/40142331/chip-stocks-staring-at-another-bloodbath-as-intel-tumbles-nvidia-dips-4-asml-crumbles-over-6-whats-a" target="_blank" rel="noopener" data-google-interstitial="false">기술 분야가 급락</a>했다. 지난주에 해당 부문을 끌어온 요인에 대한 요약과 이러한 주식이 단기 및 중기적으로 어디로 향하고 있는지에 대한 전망은 다음과 같다.
엇갈린 기술업계 실적, 지정학적 요인의 압박: 많은 거대 기술 기업들의 실적 보고서를 기다리면서 트레이더들이 신중한 태도로 시작한 기술 주식은 약간의 승리로 한 주를 시작했다. 그들은 일부 기술 부문의 실적 실망과 임박한 촉매제에 대한 경고로 인해 화요일에 눈에 띄게 약세로 돌아섰다.
어드밴스드 마이크로 디바이시스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>)의 강력한 실적 보고서는 수요일 기술주 반등을 촉진했지만 목요일 거시적 우려로 인해 매도 압력이 다시 촉발되었다. 제조 부문과 고용 시장에 대한 별도의 보고서는 트레이더들이 메타 플랫폼스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>)의 상당히 탄탄한 실적을 크게 무시하면서 해당 부문의 실패로 판명되었다.
인텔(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>)의 실적이 부진하고 엔비디아(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)에 대한 연방거래위원회(FTC)의 조사 가능성이 보고되면서 기술주에 대한 트레이더들의 위험 선호도가 약화되면서 매도 압력이 금요일까지 확대되었다.
지난주 기술주 매도에 대해 웨드부시(Wedbush)의 애널리스트인 다니엘 아이브스(Daniel Ives)는 &#8220;완벽한 폭풍으로 인한 공포가 기술주 매도를 가속화했다. 취약한 일자리 보고서가 &#8216;R 단어&#8217;에 대한 두려움을 부추기고, 연준(연방준비제도)이 금리 인하 주기에 너무 늦었다는 우려로 인해 기술주가 이 5등급 폭풍 매도의 중심에 있다&#8221;고 말했다.
8월 2일로 끝난 주의 주요 기술주와 상장지수펀드의 성과는 다음과 같다:
<ul>
<li>iShares Semiconductor ETF(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOXX#NASDAQ">SOXX</a>): -9.84%</li>
<li>Invesco QQQ Trust(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>): -3.07%</li>
<li>Vanguard Information Technology Index Fund ETF Shares(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VGT#NYSE">VGT</a>): -4.90%</li>
<li>Direxion Daily Semiconductor Bull 3X Shares(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOXL#NASDAQ">SOXL</a>): -30.01%</li>
<li>T-Rex 2X Long NVIDIA Daily Target ETF(CBOE: NVDX): -12.21%</li>
<li>엔비디아: -5.12%</li>
<li>인텔: -31.48%</li>
<li>AMD: -5.35%</li>
<li>Arm 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>): -23.86% (이번 분기 실적의 일부 손실)</li>
<li>애플(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>): +0.87%</li>
</ul>
100대 비금융 기술주 성과를 추적하는 나스닥 100 지수가 지난주의 매도세 이후 조정 영역에 진입했다. 나스닥 100 지수는 7월 11일 장중 최고치인 18,671.07에서 10% 조금 넘게 하락했다. 최근 고점 대비 10% 이상 하락하는 것을 주식시장 용어로는 조정이라고 한다.
또한 읽기: <a href="https://www.benzinga.com/money/best-tech-stocks" target="_blank" rel="noopener" data-google-interstitial="false">현재 최고의 기술주</a>
다음은 (What Lies Ahead)? 아이브스는 이러한 기술 강세장과 기술주에 대한 역사적인 상승은 끝나지 않았다고 말한다. 그는 "이것은 손에 쥐고 있어야 하는 기술주에 대한 다년간의 강세장에서 한 순간에 불과하다"고 말했다.
이 분석가는 연착륙을 요구했으며 연준이 향후 18개월 동안 대규모 금리 인하 주기를 시작할 것으로 예상했다.
기술주에 대한 아이브스의 낙관주의는 주로 인공지능 기술에 대한 그의 자신감을 전제로 한다.
그는 &#8220;우리는 이것이 기술 생태계 전반에 걸쳐 성장률을 가속화하면서 앞으로 수년 동안 더 광범위한 기술 부문을 촉진할 4차 산업 혁명이 될 1조 달러 규모의 AI Cap Ex(자본 지출) 주기의 초기 단계라고 굳게 믿고 있다&#8221;고 말했다.
이번 6월 분기 실적 시즌은 웨드부시의 강세론과 대규모 클라우드 구축에 대한 현장 점검을 입증했다고 아이브스가 말했다.
&#8220;미국 소비자 약화에 대한 우려(아마존 소비자 지출 감소), 연준의 대응 지연, 경기 경착륙 및 약세 시장 논리 재등장에 대한 걱정을 충분히 이해하지만, 우리는 기술 지출과 이 대규모 AI 기술 구축에서 중심에 설 승자들에게 집중하고 있다. 이 게임은 아직 9회 중 2회에 불과하다&#8221;라고 그가 말했다.
연준이 금리 인하를 시작할 것이라는 전망은 거대주에는 부정적이지만 중소형(SMID) 기술주에는 긍정적일 수 있다. 또한, 대선을 계기로 과잉규제 문제도 부각되고 있다. 공화당의 승리는 많은 사람들에게 규제 환경이 훨씬 덜 엄격해지는 결과로 간주된다.
AI를 활용하는 또 다른 이름인 팔란티어 테크놀로지스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>)는 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40129511/palantir-faces-critical-prove-me-moment-analyst-says-commercial-growth-will-be-star" target="_blank" rel="noopener" data-google-interstitial="false">이번 주 실적을 발표할 예정</a>이며 잠재적으로 AI 물결의 강점에 대한 통찰력을 제공할 것이다. 경제적 측면에서는 두 가지 서비스 부문 활동 수치와 실업수당 청구 등 주목할 만한 발표가 있어 상황이 다소 느려질 가능성이 높다.
<a href="https://benzinga.grsm.io/register174" target="_blank" rel="noopener">Benzinga Pro</a>의 데이터에 따르면 QQQ는 금요일 2.37% 하락한 448.75달러에 종료했다.
다음 읽기: 
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%ec%95%a0%ed%94%8c-%ec%98%88%ec%83%81%ec%9d%84-%eb%84%98%eb%8a%94-3%eb%b6%84%ea%b8%b0-%ec%8b%a4%ec%a0%81-%eb%b0%8f-%ea%b8%b0%ea%b8%b0-%ec%84%a4%ec%b9%98-%eb%8c%80%ec%88%98-%ec%97%ad%eb%8c%80/" target="_blank" rel="noopener">애플: 예상을 넘는 3분기 실적 및 기기 설치 대수 역대 최고치 돌파에도 중국 매출은 감소</a></li>
</ul>
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

ETF Opportunities Trust T-Rex 2X Long NVIDIA Daily Target ETF

뉴스

에 대한 최신 뉴스 ETF Opportunities Trust T-Rex 2X Long NVIDIA Daily Target ETF (BATS:NVDX)

화요일, 3월 18, 2025

일요일, 8월 04, 2024

뉴스

파트너 / 기고자

벤징가 글로벌